Category

News
Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the global CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of...
Continue Reading
On January 3, 2019, Takeda announced multiple research collaborations involving the development of chimeric antigen receptor T-cell (CAR-T) therapies for various cancers, and the company is working with Memorial Sloan Kettering Cancer Center (MSKCC) on the approach.1 One of the therapies under investigation is for the treatment of multiple myeloma. “We are excited by the recent momentum...
Continue Reading
Multiple myeloma is a type of blood cancer that affects the plasma cells located in the bone marrow of the body. During an infection, when B cells or B lymphocytes mature, they become plasma cells, which, in turn, are responsible for the production of antibodies or immunoglobulins. Therefore, multiple myeloma is a condition when these...
Continue Reading
The ‘Global and Southeast Asia Multiple Myeloma Drugs Industry, 2013-2023 Market Research Report’ is a professional and in-depth study on the current state of the global Multiple Myeloma Drugs industry with a focus on the Southeast Asia market. The report provides key statistics on the market status of the Multiple Myeloma Drugs manufacturers and is...
Continue Reading
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to other therapies. The decision by the Therapeutic Goods Administration (TGA) means that myeloma patients in Australia will be the first to have access to this medication. Specifically, Aplidin was approved for patients who relapsed after three lines of...
Continue Reading
The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate (ORR) of 83.3%, with a very good partial response (VGPR) or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma, according to initial results from a phase I study presented at the 2018 ASH Annual Meeting.1 In the preliminary results from the...
Continue Reading
AIMS: Multiple myeloma is a genomically complex haematological malignancy with many genomic alterations recognised as important in diagnosis, prognosis and therapeutic decision making. Here, we provide a summary of genomic findings identified through routine diagnostic next-generation sequencing at our centre.  METHODS: A cohort of 86 patients with multiple myeloma underwent diagnostic sequencing using a custom...
Continue Reading
A therapeutic drug, called lenalidomide, has shown improved outcomes and survival rates in patients with a serious type of bone marrow cancer (multiple myeloma), according to a largest of its kind of study. The study published in The Lancet Oncology, show an improvement for those who received ongoing therapy with the drug lenalidomide, compared to those not receiving...
Continue Reading
Understanding the proliferation of malignant myeloma cells can only be discerned by going back to the biology of the disease, explained Sundar Jagannath, MD, and greater understanding of a patient’s cytogenetics may compound the success seen with chemotherapy and novel adoptive cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapy. “At the moment, the...
Continue Reading
Chimeric antigen receptor T-cell therapy has improved health outcomes at a more cost-effective rate than other cancer treatments, according to a study presented at ASH Annual Meeting and Exposition. Data suggest that price increases of pharmaceutical oncology treatments have outpaced survival improvements. However, these study findings reveal that chimeric antigen receptor (CAR) T-cell therapy represents...
Continue Reading
1 2 3 4 14

Floor 7, 90 The Terrace
Wellington Central
New Zealand